Estimates Revisions Bristol-Myers Squibb Company

Equities

Real-time Estimate Cboe BZX Other stock markets 04:00:00 2026-01-13 pm EST			5-day change	1st Jan Change
56.42 ^USD	+1.17%		+2.80%	+3.72%

10:43am	Leerink Partners Adjusts Price Target on Bristol-Myers Squibb to $60 From $54, Maintains Outperform Rating	MT
Jan. 12	Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy	CI

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	1m. Revenue rev.	1y. Revenue rev.	1y. EPS revision
	BRISTOL-MYERS SQUIBB COMPANY
	ELI LILLY AND COMPANY
	JOHNSON & JOHNSON
	ABBVIE INC.
	ROCHE HOLDING AG
	ASTRAZENECA PLC
	MERCK & CO., INC.
	NOVARTIS AG
	NOVO NORDISK A/S
	AMGEN INC.
	Average
	Weighted average by Cap.